Annual Report

Overview

The report presents SynAct Pharma's 2024 progress as focused on clinical development, with the ADVANCE Phase 2b study initiated in newly diagnosed severe RA and recruitment planned for 240 patients. It also describes continued development of the TXP peptide portfolio, with TXP-11 in preclinical development and Phase 1 readiness targeted for 2026. Financially, the Group reported no net sales and R&D costs of SEK 49,312 thousand.

Document

Report type: Annual Report
Class: Financial
Scope: Full report
Fiscal year: 2024
Period: 1 January 2024 – 31 December 2024
Language: English
Pages
File size

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services